Want to see JP:4584 full AI Analyst Report?
4584 Stock Chart & Stats
¥203.00
¥2.00(1.89%)
At close: 4:00 PM EST
¥203.00
¥2.00(1.89%)
Day’s Range― - ―
52-Week Range¥125.00 - ¥320.00
Previous CloseN/A
Volume149.00K
Average Volume (3M)306.40K
Market Cap
¥8.30B
Enterprise Value¥6.45K
Total Cash (Recent Filing)¥3.23B
Total Debt (Recent Filing)¥2.48B
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Nov 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.60
Shares Outstanding50,582,990
10 Day Avg. Volume361,250
30 Day Avg. Volume306,400
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)7.17
Price to Sales (P/S)1.80
P/FCF Ratio-10.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)19.3
Revenue Forecast (FY)¥4.92B
Bulls Say, Bears Say
Bulls Say
Commercial Scale-upThe substantial multi-year revenue increase indicates that Kidswell Bio has expanded commercial traction and market reach. A larger revenue base can improve operating leverage over time if the company can stabilize margins and control development and selling costs.
Positive Gross MarginPositive gross margin shows that the underlying products generate value above direct costs, supporting the potential for eventual profitability. Although compressed margins are a concern, maintaining positive product-level economics provides a foundation for improvement through scale and portfolio management.
Balance-sheet RecoveryImproved equity from the 2024 low provides some balance-sheet recovery and may strengthen resilience relative to the company’s weakest period. This does not eliminate leverage risk, but it offers a better capital base for funding operations and future development than in 2024.
Bears Say
Elevated LeverageLeverage remains high for a company with inconsistent profitability, increasing refinancing and interest-burden risk. Debt reduces financial flexibility when operating results weaken and may constrain investment in biologic development, commercialization, or other growth initiatives.
Unstable Cash GenerationThe reversal from strong positive cash flow in 2025 to material burn in 2026 demonstrates that internal funding is not yet dependable. Repeated negative operating cash flow can increase reliance on financing, dilute shareholders, and limit flexibility during development or commercial setbacks.
Recurring Losses And Margin PressureA return to losses after near break-even performance shows that profitability is not established. Margin volatility and compression reduce the company’s ability to absorb fixed operating costs, making sustainable earnings dependent on execution, product mix, and renewed revenue growth.
Kidswell Bio Corporation News
4584 FAQ
What was Kidswell Bio Corporation’s price range in the past 12 months?
Kidswell Bio Corporation lowest stock price was ¥125.00 and its highest was ¥320.00 in the past 12 months.
What is Kidswell Bio Corporation’s market cap?
Kidswell Bio Corporation’s market cap is ¥8.30B.
When is Kidswell Bio Corporation’s upcoming earnings report date?
Kidswell Bio Corporation’s upcoming earnings report date is Nov 11, 2026 which is in 63 days.
How were Kidswell Bio Corporation’s earnings last quarter?
Kidswell Bio Corporation released its earnings results on Aug 13, 2026. The company reported ¥3.99 earnings per share for the quarter.
Is Kidswell Bio Corporation overvalued?
According to Wall Street analysts Kidswell Bio Corporation’s price is currently Overvalued.
Does Kidswell Bio Corporation pay dividends?
Kidswell Bio Corporation does not currently pay dividends.
What is Kidswell Bio Corporation’s EPS estimate?
Kidswell Bio Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kidswell Bio Corporation have?
Kidswell Bio Corporation has 50,582,990 shares outstanding.
What happened to Kidswell Bio Corporation’s price movement after its last earnings report?
Kidswell Bio Corporation reported an EPS of ¥3.99 in its last earnings report. Following the earnings report the stock price went up 2.703%.
Which hedge fund is a major shareholder of Kidswell Bio Corporation?
Currently, no hedge funds are holding shares in JP:4584
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kidswell Bio Corporation
Kidswell Bio Corporation, headquartered in Tokyo, Japan, specializes in the development of pharmaceutical treatments for rare and complex diseases. The company, which was founded in 2001 and operated as Gene Techno Science Co.,Ltd. until rebranding in July 2021, maintains a robust pipeline of therapeutic candidates. This includes GND-004, designed for both ophthalmic conditions and oncology, and GND-007, aimed at immunological disorders. Their portfolio also features a range of antibodies being developed for cancer therapies. Further expanding its research, the GBS series encompasses GBS-001, GBS-004, and GBS-010 for oncology; GBS-005 for immunological diseases; GBS-007 and GBS-012 for eye-related ailments; GBS-008 for infectious diseases; and GBS-011 for renal conditions. Additionally, Kidswell Bio is progressing GCT-101 for alveolar clefts, GCT-102 for congenital isolated hypoganglionosis, alongside other investigational products addressing ophthalmologic disorders, cerebral palsy, peripheral nerve palsy, fractures, and spinal cord injuries.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―